U.S. markets closed

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
24.48-2.55 (-9.43%)
At close: 04:00PM EST
24.35 -0.13 (-0.53%)
After hours: 07:46PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Down

Gap Down

Previous Close27.03
Bid24.35 x 1400
Ask24.48 x 1000
Day's Range23.09 - 26.27
52 Week Range23.09 - 133.00
Avg. Volume684,526
Market Cap4.579B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.90
Earnings DateApr 13, 2022 - Apr 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.41
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CVAC

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CureVac N.V.
    Analyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.
    Fair Value
    Economic Moat
    12 days agoMorningstar
View more

    CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

    TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 17, 2022 / CureVac N. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the company's Chief Technology Officer, Dr.

  • Motley Fool

    Why CureVac Stock Is Sinking Today

    What happened Shares of vaccine maker CureVac (NASDAQ: CVAC) were sinking 10.8% lower as of 10:43 a.m. ET on Friday. The decline came after investment company dievini and the German government announced the signing of a revised shareholder agreement on Thursday related to their shares in CureVac.


    dievini and the Federal Republic of Germany Amend Shareholders’ Agreement Regarding Investments in CureVac N.V.

    BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt für Wiederaufbau (KfW) and the investment company dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.